Form 4: Eli Lilly Director Acquires Shares Through Deferral Plan

Kimberly H. Johnson, a director at Eli Lilly & Co, acquired 13 shares of common stock through a deferral plan.

Summary

• Kimberly H. Johnson, a director of Eli Lilly & Co, acquired 13 shares of common stock on March 18, 2024.
• The shares were acquired at a price of $762.66 per share.
• These shares were acquired through the Lilly Directors' Deferral Plan, in lieu of cash compensation.
• The shares will be settled in common stock following Johnson's separation from service.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed neutrally to slightly positive as it aligns director interests with shareholders.

Positives

• The acquisition of shares by a director may signal confidence in the company's future performance.

Future Outlook

The acquired shares will be settled in common stock following the director's separation from service.

Industry Context

This is a routine transaction related to director compensation and is not unusual for publicly traded companies.

Comparison to Industry Standards

• Director share acquisitions through deferral plans are a common practice among large publicly traded companies like Eli Lilly.
• These plans are often used to align the interests of directors with those of shareholders.
• Similar plans are used by companies such as Pfizer, Merck, and Johnson & Johnson.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns director interests with the company's performance.

Key Dates

Keywords

Eli Lilly, Director, Share Acquisition, Deferral Plan, LLY, Stock Units, Kimberly H. Johnson